Usefulness of sotalol for drug-refractory malignant ventricular arrhythmias  by Gonzalez, Rolando et al.
1568 JACC Vol. 12, No.6 
December 1988: 1568-72 
Usefulness of Sotalol for Drug-Refractory Malignant 
Ventricular Arrhythmias 
ROLANDO GONZALEZ, MD, MELVIN M. SCHEINMAN, MD, FACC, 
JOHN M. HERRE, MD, FACC, JERRY C. GRIFFIN, MD, FACC, 
MARY JANE SAUVE, RN, DNSc, HUGH SHARKEY, RN 
San Francisco, California 
Fifty patients with recurrent sustained symptomatic ven-
tricular tachycardia (43 patients) or ventricular fibrillation 
(7 patients) resistant to a mean of 2.8 + 1.4 antiarrhythmic 
drugs were treated with sotalol, a beta-adrenergic receptor 
antagonist, and 45 underwent invasive electrophysiologic 
testing before and after sotalol therapy. The arrhythmia 
became noninducible in 10, was slower and hemodynami-
cally well tolerated in 12 and was poorly tolerated in 23. 
Four patients were empirically treated with long-term 
administration of oral sotalol as were 21 patients who either 
had noninducible arrhythmia (10 patients) or had hemody-
namically stable ventricular tachycardia (11 patients). 
In these 25 patients treated with long-term administra-
tion of sotalol, there was no recurrence of ventricular 
tachycardia in the group with noninducible arrhythmia, 
Sotalol is ari antiarrhythmic agent with unique electrophys-
iologic properties. These include the ability to greatly pro-
long action potential duration (class III effect) and beta-
adrenergic blocking properties (1-3). Previous reports (4-6) 
contain limited experience in the use of this drug in patients 
with sustained ventricular tachycardia or ventricular fibril-
lation and even less information is available on the role of 
this drug in patients who prove intolerant or refractory to 
amiodarone. Prior electrophysiologic studies (4-6) in pa-
tients with sustained ventricular tachycardia or ventricular 
fibrillation used induction protocols that are less aggressive 
than those currently accepted. The purpose of the present 
study was to evaluate the safety and efficacy of sotalol in 
patients with diverse cardiac disease who presented with 
ventricular tachycardia or ventricular fibrillation refractory 
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whereas 37% of patients with inducible ventricular tachy-
cardia had new ventricular tachycardia or sUdden death. 
Programmed ventricular stimulation with up to three ex-
trastimuli proved to be an excellent predictor of drug 
efficacy and a good predictor of inefficacy. A positive prior 
response to amiodarone was not a reliable indicator of a 
positive response to sotalol. 
Side effects included those attributed to both beta-
adrenergic blockade as well as proarrhythmic effects. The 
latter were observed in two of four patients with a QT 
interval >600 ms. Sotalol was found to be effective therapy 
for a subset of patients with ventricular tachycardia unre-
sponsive to type IA drugs. 
(J Am Coll CardioI1988;12:1568-72) 
to standard antiarrhythmic drugs and to assess the predictive 
value of invasive electrophysiologic studies in these pa-
tients. 
Methods 
Study patients. The efficacy of sotalol for treatment of 
ventricular tachycardia was evaluated in 50 patients, all of 
whom had a history of either symptomatic sustained ventric-
ular tachycardia (> 30 s) (43 patients) or ventricular fibrilla-
tion (7 patients). There were 41 men and 9 women with a 
mean age of 59 ± 14 years (range 25 to 79). Only patients 
with documented sustained monomorphic ventricular tachy-
cardia or ventricular fibrillation were included in the study. 
Excluded were those with acute cardiac processes (that is, 
acute myocardial infarction or myocarditis) and those with a 
left ventricular ejection fraction <20%. Symptoms associ-
ated with spontaneously occurring ventricular tachycardia 
included severe dyspnea, pulmonary edema, hypotension, 
chest pain, syncope or cardiovascular collapse. Forty-nine 
patients had evidence of organic heart disease, whereas only 
I 
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one patient had no evidence of heart disease. Cardiac 
diagnoses included coronary artery disease (36 patients), 
idiopathic dilated cardiomyopathy (7 patients), arrhythmo-
genic right ventricular dysplasia (3 patients), hypertrophic 
cardiomyopathy (2 patients) and cardiac sarcoidosis (1 
patient). 
All patients except one had been unsuccessfully treated 
with at least one class IA antiarrhythmic drug and most 
patients had been treated with more than one antiarrhythmic 
agent by the time of referral. None had been treated with full 
beta-blocking doses of a conventional beta-adrenergic 
blocker. The mean number of previously ineffective drugs 
was 2.8 + 1.4 drugs per patient. Eleven patients had their 
ventricular tachycardia well controlled with amiodarone. 
These patients were successfully treated with amiodarone 
for 0.8 to 4.4 years (mean ± SD, 2.9 ± 1.5), but the drug had 
been withdrawn because of toxic side effects. 
Baseline electrophysiologic studies were performed in 48 
of the patients, whereas in 2 patients sotalol therapy was 
initiated to treat frequent spontaneous episodes of ventricu-
lar tachycardia. Of the 50 patients, 45 had a repeat elec-
trophysiologic study performed while taking oral sotalol 
therapy. In the other five patients, repeat study was not 
performed because of the lack of a baseline study (two 
patients), spontaneous recurrence of the arrhythmia (one 
patient), a side effect precluding long-term drug use (one 
patient) or refusal to undergo a repeat study (one patient). 
Study protocol. All patients were admitted to the hospi-
tal, and previously used antiarrhythmic drugs were discon-
tinued for at least five half-lives. In those previously treated 
with amiodarone, the drug was discontinued for 2: 1 month 
and until the serum amiodarone level was <0.3 mglliter. 
Cardiac function was evaluated by either echocardiography 
or gated nuclear blood pool studies, or both, and a 24 h 
ambulatory recording was obtained. A baseline electrophys-
iologic study was performed and patients were monitored 
either in the coronary care unit or in a cardiac telemetry unit. 
The initial dose of sotalol used was 80 mg twice a day and the 
dose titrated upward to a maximal dose of 320 mg twice a 
day. The patients underwent restudy after demonstrating 
tolerance to the largest dose of sotalol used. In two patients 
the maximal tolerated dose was 80 mg twice a day. The 
repeat electrophysiologic study was performed after six 
doses of a given drug regimen and all studies were performed 
just before the morning sotalol dose. 
Long-term outpatient oral sotalol therapy was used only 
in those patients whose arrhythmia was either non inducible 
during oral therapy or whose induced ventricular tachycar-
dia was hemodynamically stable. Hemodynamically stable 
ventricular tachycardia was defined as ventricular tachycar-
dia that was slower than the rate before treatment and was 
not associated with dizziness, presyncope, dyspnea or hy-
potension (pressure :s90 mm Hg). In addition, long-term oral 
therapy was used in four patients who did not undergo a 
repeat study. The patients were carefully monitored for new 
arrhythmias or other drug side effects. They were all fol-
lowed up by one of us both in the cardiac arrhythmia clinic 
and with use of a transtelephonic follow-up protocol (Sur-
vival Technology). 
Electrophysiologic study protocol. After written informed 
consent was obtained, patients were studied in the postab-
sorptive state. Our protocol for programmed ventricular 
stimulation has been described previously in detail (7). In 
brief, it consisted of use of up to triple extrastimuli at the 
right ventricular apex and outflow tract during sinus rhythm 
and at least two different ventricular drive cycles (600 and 
400 ms) (7). The end point of study was induction of 
sustained monomorphic ventricular tachycardia (>30 s) or 
ventricular fibrillation. In those with stable ventricular 
tachycardia at least two inductions were completed. A 
similar induction protocol involving repeat catheterization 
was used after patients were in stable condition during oral 
sotalol therapy. 
Statistical methods. Differences in variables before and 
after administration of sotalol were compared with use of an 
analysis of paired samples (t test). 
Results 
Baseline electrophysiologic studies. A total of 48 patients 
underwent baseline electrophysiologic studies, and sus-
tained ventricular tachycardia was induced in all patients. 
Tachycardia was induced with a single ventricular extrastim-
ulus during sinus rhythm in 2 patients and during ventricular 
drive in 5, double extra stimuli in 24, triple ventricular 
extrastimuli in 16 and ventricular overdrive pacing in 1. The 
induced ventricular tachycardia was terminated by ventric-
ular overdrive pacing in 38 patients. In one patient, ventric-
ular tachycardia spontaneously degenerated into ventricular 
fibrillation, in the remaining nine patients, ventricular pacing 
resulted in overdrive acceleration. These 10 patients each 
required a single direct current countershock for ventricular 
tachycardia termination. In two patients with stable ventric-
ular tachycardia, induced ventricular tachycardia differed 
from that recorded during spontaneous episodes. 
Electrophysiologic studies after sotalol therapy. A total of 
46 patients with inducible ventricular tachycardia were 
started on sotalol therapy for repeat electrophysiologic 
study. One patient developed sustained ventricular tachy-
cardia the morning before the study and sotalol was discon-
tinued. The remaining 45 patients underwent study after oral 
sotalol therapy. Sotalol blood levels were obtained at com-
pletion of the electrophysiologic study in 13 of the 45 
patients and the mean level was 2,283 ± 443 ng/ml (range 
1,828 to 3,108). For the group as a whole, after sotalol, the 
mean spontaneous sinus cycle length increased from 829 ± 
148 to 1,063 ± 177 ms (p < 0.02) as did the right ventricular 
effective refractory periods measured at a drive cycle length 
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of 600 ms (252 ± 21 to 293 + 33 ms) (p < 0.02). The QT 
interval increased after sotalol (414 ± 46 to 500 ± 59 ms) (p 
< 0.01); however, changes in the corrected QT interval (QT/ 
VRR) were not statistically significant (460 + 44 to 480 + 55 
ms). After sotalol, ventricular tachycardia was no longer 
inducible in 10 of the 45 patients. 
The group with inducible arrhythmia was further classi-
fied into two subgroups solely on the basis of whether the 
induced arrhythmias were well tolerated; one group of 23 
patients had no significant change in ventricular tachycardia 
cycle length compared with baseline determination (290 ± 74 
versus 309 ± 48 ms) and the induced ventricular tachycardia 
was not well tolerated. Inability to tolerate ventricular 
tachycardia was defined as systolic pressure of <90 mm Hg 
with or without development of dizziness, pre syncope or 
dyspnea during induced ventricular tachycardia. In contrast, 
in a second subgroup of 12 patients, the cycle length of the 
induced ventricular tachycardia increased (312 ± 62 to 406 ± 
80 ms) (p < 0.02) and the induced ventricular tachycardia 
was well tolerated. In 1 of these 12 patients, only non-
sustained ventricular tachycardia could be induced. Patients 
in the latter subgroup were treated with long-term oral 
sotalol therapy. 
Comparison of patients with inducible versus noninducible 
ventricular tachycardia. There was no significant difference 
between the inducible and noninducible group with respect 
to cardiac diagnosis, mean age (59 ± 12 versus 57 ± 14 
years), ejection fraction (41 ± 14 versus 42 ± 12%), baseline 
ventricular tachycardia cycle length (298 ± 69 versus 291 ± 
75 ms), sotalol blood levels (2,178 + 237 versus 2,480 + 382 
ng/ml), changes in the ventricular effective refractory period 
after sotalol (249 ± 22 to 296 ± 36 versus 253 ± 21 to 286 ± 
26) or number of unsuccessful antiarrhythmic drug trials 
before sotalol evaluation (3.10 ± 1.4 versus 2.4 + 1.2). 
Although the mean daily dose of sotalol was less for the 
inducible group (461 ± 153 mg/day) than for the non inducible 
group (528 + 152 mg/day), this difference was not statisti-
cally significant. 
Patient follow-up (noninducible group). Long-term oral 
sotalol therapy was initiated for the 10 patients whose 
ventricular tachycardia was noninducible after drug therapy. 
Sotalol was discontinued in one patient who developed 
polymorphous ventricular tachycardia on the 4th hospital 
day while taking 320 mg twice a day. The other nine patients 
were discharged on sotalol therapy. The drug was discontin-
ued in two patients: in one because of severe depression and 
in one because of fatigue and symptomatic hypotension. 
Over a follow-up period of 20 ± 17 months (range 4 to 48), 
the remaining seven patients received a mean daily dose of 
525 + 152 mg of sotalol and have had no ventricular 
tachycardia or drug side effects. 
Patient follow-up (inducible group). A total of 12 patients 
with slower, hemodynamically stable ventricular tachycar-
dia were started on oral sotalol therapy. Sotalol was discon-
tinued in one patient who developed aggravation of ventric-
ular tachycardia on the 4th day while taking 320 mg twice a 
day. The other 11 patients were discharged on oral sotalol 
therapy. The drug was discontinued in three patients be-
cause of heart failure or fatigue, or both, which appeared 0.5, 
4 and 5 months, respectively, after initiation of therapy. 
Three of the 11 patients developed recurrent ventricular 
tachycardia between 2 and 7 months after initiation of sotalol 
and 1 of these 3 patients died suddenly during a documented 
episode of ventricular tachycardia. An additional 5 of the 11 
patients in this subgroup have had no recurrence of ventric-
ular tachycardia or toxic drug side effects. 
Four patients who did not undergo repeat study were also 
discharged on sotalol therapy and one developed recurrent 
ventricular tachycardia and died of the arrhythmia. Of the 
remaining three patients, one had intolerable side effects 
associated with hypotension and only two remained on 
treatment with arrhythmia control and with no side effects. 
Previous treatment with amiodarone. Eleven patients 
whose ventricular tachycardia was well controlled with 
amiodarone therapy over a mean period of 2.9 ± 1.5 years 
had to discontinue amiodarone therapy becaust,; of side 
effects. These effects consisted of peripheral neuropathy in 
three patients, pulmonary toxicity in six, optic neuritis in 
one and hypothyroidism in one. For this group of patients, 
the mean age was 64 ± 8 years and ejection fraction 38 ± 
14%; all but three had coronary artery disease. Baseline 
electrophysiologic testing was performed in 10 of the 11 
patients, and in all 10, ventricular tachycardia was induced 
with either double (7 patients) or triple (3 patients) extra-
stimuli. Baseline ventricular tachycardia cycle length was 
289 + 53 ms. Nine of the 11 patients had an electrophysio-
logic study while receiving sotalol; ventricular tachycardia 
was induced in all. Whereas the ventricular tachycardia 
cycle length was prolonged (from 301 ± 51 at baseline to 357 
± 83 ms on therapy), this difference was not significant. In 
addition, there was no difference in the ease of ventricular 
tachycardia inducibility before and after sotalo!. Eight of the 
11 patients previously treated with amiodarone were dis-
charged from the hospital on long-term oral sotalol therapy 
and 3 (37%) of these 8 had documented recurrent ventricular 
tachycardia 5 months after the initiation of sotalol therapy. 
Side effects. Eight of the patients developed side effects 
that forced discontinuation of the drug. Three patients 
developed early (in-hospital) side effects, including recurrent 
episodes of polymorphous ventricular tachycardia in one 
and of monomorphic ventricular tachycardia in another. 
Both patients showed marked prolongation of the QT inter-
val (680 and 600 ms, respectively). A third patient with 
hypertrophic cardiomyopathy and an ejection fraction of 
30% developed severe congestive heart failure. 
The remaining five patients developed symptoms after 
hospital discharge; one with ,an ejection fraction of 32% 
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developed congestive heart failure and bronchospasm and 
attempted reduction of dose to 160 mg twice a day was 
associated with ventricular tachycardia recurrence. Two 
patients developed profound fatigue, one developed dizzi-
ness and hypotension and one developed severe depression 
after sotalol therapy. Of six patients with an ejection fraction 
<32% who were treated for >2 months, three developed 
either overt congestive heart failure (two patients) or severe 
fatigue (one patient). 
Discussion 
Clinical efficacy of sotalol therapy. The primary role of 
this study was to assess the clinical efficacy of sotalol in 
patients with drug-refractory ventricular tachycardia. We 
found that in 20% of patients refractory to class IA drugs 
their tachycardia became noninducible when electrical stim-
ulation was performed during sotalol therapy. The incidence 
of noninducibility after sotalol in our study was lower than 
that recorded by others (67% by Senges et al. [4], 45% by 
Nademanee et al. [5] and 35% by Steinbeck et al. [6]). These 
differences could be related to our more aggressive stimula-
tion protocol because we used up to three extra stimuli as 
opposed to the two extrastimuli used by others. In addition, 
we found that patients whose tachycardia was non inducible 
and who were able to tolerate long-term therapy remained 
free of recurrent ventricular tachycardia or ventricular fibril-
lation. In our series, all patients whose tachycardia was 
noninducible and who could take sotalol (absence of side 
effects) remained free of ventricular tachycardia-ventricular 
fibrillation, whereas 37% of patients with inducible tachycar-
dia had recurrent ventricular tachycardia-ventricular fibril-
lation during oral sotalol therapy. This observation is in 
accordance with the results of Steinbeck et al. (6). In their 
series of 12 patients who had sustained ventricular tachycar-
dia and a positive response to sotalol during baseline study, 
only 1 developed sustained ventricular tachycardia (8%) 
during long-term oral sotalol therapy, whereas 5 of the 5 
patients with persistent inducibility had recurrence of their 
ventricular tachycardia. In the experience of Nademanee et 
al. (5), 4 (33%) of 12 patients with non inducible tachycardia 
had recurrent ventricular tachycardia on follow-up, and 6 of 
the 10 with inducible tachycardia had recurrent ventricular 
tachycardia on follow-up. The poorer prediction of efficacy 
in the series of Nademanee et a!. compared with our own 
may be due to use of double extrastimuli in their study. Our 
observations suggest that testing with triple extrastimuli 
provides excellent prediction of drug efficacy but may be a 
less reliable predictor of inefficacy. 
Sotalol and amiodarone. Because both sotalol and amio-
darone prolong the action potential duration, one hypothesis 
we tested was the possible crossover in efficacy between 
these two drugs. Our preliminary observations suggest that a 
positive response to amiodarone therapy does not predict a 
similar response to sotalol. 
Side effects. Three patients experienced early side effects 
whereas five had late side effects that forced discontinuation 
of the drug. These side effects included those typical for 
beta-adrenergic blockers (that is, heart failure, broncho-
spasm, depression, fatigue and hypotension) as well as 
proarrhythmic effects. The side effects reported in previous 
studies included mild hypotension and bradycardia that did 
not require discontinuation of the drug in any patient (6); 
sick sinus syndrome that required a permanent pacemaker 
implant (2 of22 patients) (6); symptomatic sinus bradycardia 
and cardiac arrest that required discontinuation of the drug 
(4); lethargy, weakness, depression, heart failure and brady-
cardia in 4 of 25 patients (5) and torsade de pointes in 1 of 17 
patients (4). The higher incidence of side effects in our series 
may be related to higher drug dosage. Of note is that in our 
series, three of the four patients who developed heart failure 
or profound fatigue had an ejection fraction in the range of 30 
to 32% and that the two patients who developed proarrhyth-
mic effects had marked prolongation of the QT interval at the 
time of their arrhythmia (600 and 680 ms, respectively). 
Thus, two of four of patients with a QT interval >600 ms 
developed either incessant ventricular tachycardia or tor-
sade de pointes. Our data suggest that a QT interval 2:600 ms 
may be associated with increased risk of proarrhythmic 
events. 
Limitations of study. The chief limitation of our study is 
the relatively small number of patients discharged on long-
term sotalol therapy. Prior studies used only double ventric-
ular extrastimuli for their tachycardia induction protocols 
and our study may be criticized because triple extrastimuli 
might falsely predict a higher incidence of failures (8). Of 10 
patients whose tachycardia was noninducible after double 
extrastimuli but inducible with triple extrastimuli, 4 were 
discharged on long-term oral sotalol therapy; on follow-up, 
spontaneous ventricular tachycardia occurred in 2 of the 4. 
We would argue that a protocol providing a 100% prediction 
of efficacy at the expense of overpredicting failures is a more 
prudent clinical approach compared with protocols that 
might overestimate true drug efficacy. 
Clinical implications. Our results suggest that sotalol 
therapy may be effective for selected patients with ventric-
ular tachycardia who do not respond to or cannot tolerate 
conventional antiarrhythmic agents. Electrophysiologic 
studies are recommended to better predict long-term drug 
efficacy. For example, non inducibility of arrhythmias ap-
pears to be the most reliable therapeutic end point, whereas 
induction of hemodynamically tolerable ventricular tachy-
cardia predicts a less desirable outcome (37% recurrence 
rate). Patients with sustained ventricular tachycardia-
ventricular fibrillation should receive the drug during in-
hospital continuous electrocardiographic monitoring and the 
drug should be discontinued in those with a QT interval 
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>600 ms. Caution should also be applied in the use of this 
drug in patients with depressed left ventricular ejection 
fraction «32%). 
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